| Basics |
X4 Pharmaceuticals Inc
Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.
|
| IPO Date: |
May 13, 2022 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.75M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.07 | 5.29%
|
| Avg Daily Range (30 D): |
$0.10 | 8.29%
|
| Avg Daily Range (90 D): |
$0.06 | 6.30%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.06M |
| Avg Daily Volume (30 D): |
1.94M |
| Avg Daily Volume (90 D): |
5.78M |
| Trade Size |
| Avg Trade Size (Sh.): |
274 |
| Avg Trade Size (Sh.) (30 D): |
331 |
| Avg Trade Size (Sh.) (90 D): |
443 |
| Institutional Trades |
| Total Inst.Trades: |
10 |
| Avg Inst. Trade: |
$.93M |
| Avg Inst. Trade (30 D): |
$2.54M |
| Avg Inst. Trade (90 D): |
$2.54M |
| Avg Inst. Trade Volume: |
.02M |
| Avg Inst. Trades (Per Day): |
5 |
| Market Closing Trades |
| Avg Closing Trade: |
$.53M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
14.29K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.17
|
$-.21
|
$-.22
|
|
Diluted EPS
|
$-.17
|
$-.21
|
$-.22
|
|
Revenue
|
$ .64M
|
$ .94M
|
$ .72M
|
|
Gross Profit
|
$ .18M
|
$ .31M
|
$ .25M
|
|
Net Income / Loss
|
$ -1.98M
|
$ -1.9M
|
$ -1.86M
|
|
Operating Income / Loss
|
$ -1.93M
|
$ -1.77M
|
$ -1.81M
|
|
Cost of Revenue
|
$ .46M
|
$ .64M
|
$ .47M
|
|
Net Cash Flow
|
$ 1.06M
|
$ -.73M
|
$ -.84M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 18, 2025:
1:10
|
|
Apr 19, 2023:
1:10
|
|
Mar 14, 2019:
1:6
|
|
|
|